



## ON-GOING TRIALS FOR GINECO GROUP

### ❖ OVARIAN CANCER

#### → RARE – OVARIAN CANCERS

- WEB-SITE ([www.ovaire-rare.org](http://www.ovaire-rare.org))
- Germ cell & sex cord-stromal malignant tumors
- Analysis of first 100 patients presented at ASCO 2008

➤ 157 inclusions since 03/2002



→ **ELDERLY PATIENTS / FAG 3 Study**

- Open label prospective trial
- Use of Carboplatin in first-line
- Main objective = evaluation of cancer distress on OS
- Third study of the GINECO group on this population

➤ 73 inclusions since 09/07 (target = 100)



→ **RECURRENT OVARIAN CANCER / CARTAXHY Study**

- Phase II Study – Monotherapy vs bitherapy
  - Main objective : PFS in the 3 arms
  - R
    - weekly paclitaxel
    - weekly paclitaxel + weekly topotecan
    - weekly paclitaxel + carboplatin every 4 weeks
- Recruitment closed since august 2008 : poster ASCO 2009



→ **SENSITIVE OVARIAN CANCER / CALYPSO Study**

- TC vs Caelyx-Carbo
  - End of recruitment (976 pts) since end of Sept. 07
- First efficacy results presented at ASCO 2009



## ❖ ENDOMETRIAL CANCER

→ ENDORAD Study

- Relapse or metastatic
  - Phase II trial
  - RAD 01 / Everolimus in monotherapy
  - Primary objective = non progression rate
- 27 inclusions since april 08





→ PHASE B (2008)

New combination of platinum + topotecan better tolerated

- Phase I / II trial
- Relapse or metastatic
- Weekly topo+carbo every 4 weeks
  - Beginning phase I since october 08 : 3 inclusions